-
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
31 May 2024 11:30 GMT
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of …
-
TB Vaccine Shows Protection Against COVID-19 in People With T1D
03 Jun 2024 15:05 GMT
… ;article/bcg-tb-vaccine-diseases-diabetes-multiple-sclerosis
3. Faustman DL, Wang … ;press-release/century-old-vaccine-protects-type-1-diabetics#:~:text …
-
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
28 May 2024 11:30 GMT
NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with …
-
Multiple sclerosis: blood test that tracks immune response could be first step in developing better treatments
24 May 2024 12:30 GMT
An estimated 2.8 million people worldwide have multiple sclerosis (MS). This autoimmune condition is the result of the immune system damaging parts of the nerves in the brain and spinal cord, which can lead to problems with movement, vision, balance and …
-
R&D agreement for Epstein-Barr virus vaccine
29 May 2024 16:56 GMT
SpyBiotech and The University of Oxford have a sponsored research agreement for the development of a vaccine against Epstein-Barr virus (EBV).
EBV is a commonly spread virus that can lead to several serious health conditions including infectious …
-
SpyBiotech and University of Oxford work on EBV vaccine
25 May 2024 16:55 GMT
Oxford-based SpyBiotech announced the collaboration on May 23.
EBV, a common virus linked to various cancers and multiple sclerosis, has no currently available vaccines or treatments.
The innovative project will merge the university's research …
-
SpyBiotech signed research agreement with Uni of Oxford for vaccine development
24 May 2024 04:18 GMT
SpyBiotech, an Oxford-based biotechnology company with novel vaccine platform technologies that can target infectious diseases, cancer, and chronic diseases, has secured a research agreement with The University of Oxford for the development of a vaccine …
-
Epstein-Barr Virus, Multiple Sclerosis and Cancer: Looking Back at 60 Years of Research
30 Apr 2024 11:05 GMT
The Epstein-Barr virus (EBV) was the first virus to be discovered that could cause human cancer. Since then, the virus has been implicated in the development of a range of different cancers and, more recently, in the development of multiple sclerosis (MS). …
-
Multiple sclerosis discovery could be a breakthrough
30 Apr 2024 09:08 GMT
By Lisa Jarvis
Tuesday, April 30, 2024 | 2 a.m.
We’ve made significant progress in developing better treatments for multiple sclerosis over the past two decades. Yet the medical community still struggles to diagnose the neurological condition, let alone …
-
Study Indicates Covid Vaccine May Trigger Thyroid-Related Autoimmune Disorders
16 May 2024 12:25 GMT
… . This pattern contrasts with overall vaccine-related mortality, which has been … type 1 diabetes, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Graves’ disease …